VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, has signed a nonbinding letter of intent with Denmark-based Missionpharma A/S to explore the development and global commercialization of its prototype lateral flow technology for detecting NETosis, a process associated with inflammation. The collaboration will initially focus on evaluating the finger-prick diagnostic test for neonatal sepsis, with potential applications in low- and middle-income countries and humanitarian emergency settings.
The significance of this agreement lies in its potential to address a critical unmet need in global health. Neonatal sepsis is a leading cause of infant mortality worldwide, and early identification is crucial for effective management. Volition’s lateral flow test measures circulating nucleosomes and neutrophil extracellular traps as early indicators of hyperinflammation, offering a rapid and affordable alternative to centralized laboratory testing. This could be particularly transformative in resource-constrained regions where access to sophisticated diagnostics is limited.
Missionpharma, which supplies healthcare products to United Nations agencies, government health ministries, and other institutions, brings expertise in low-cost manufacturing, clinical studies, and distribution. The partnership could accelerate the availability of this diagnostic tool in exactly the settings where it is most needed. As Volition noted in its announcement, the agreement follows recent results showing that the lateral flow prototype demonstrated high correlation with its established automated Nu.Q NETs test in critically ill sepsis patients, providing a solid foundation for further development.
The collaboration also underscores Volition’s commitment to advancing epigenetics-based diagnostics. The company is dedicated to saving lives and improving outcomes through earlier detection and monitoring of diseases. Its proprietary Nu.Q technology platform is designed to be simple, easy to use, and cost-effective, making it suitable for point-of-care applications. The potential of this technology extends beyond neonatal sepsis to other conditions associated with NETosis, such as adult sepsis and certain cancers.
For investors and industry observers, the LOI represents a strategic step toward validating and commercializing Volition’s lateral flow technology. While nonbinding, the agreement signals Missionpharma’s interest in leveraging its global distribution networks and manufacturing capabilities to bring the test to market. The collaboration could also facilitate clinical studies necessary for regulatory approvals and widespread adoption.
The full details of the announcement are available in the press release, which can be accessed through this link. As the partnership progresses, it will be important to monitor developments regarding the evaluation of the test’s performance in field settings and the timeline for potential commercialization. The outcome could have significant implications for global health initiatives aimed at reducing neonatal mortality and improving sepsis management in vulnerable populations.
Volition’s efforts are part of a broader trend of companies developing point-of-care diagnostics for infectious diseases and inflammatory conditions. The ability to detect NETosis rapidly and accurately could enable earlier intervention and better patient outcomes. With Missionpharma’s involvement, the technology has a promising pathway to reach the communities that need it most.
This news is also being distributed through NetworkNewsWire, a specialized communications platform, and is part of a Dynamic Brand Portfolio at IBN, which provides various corporate communications solutions. For more information on the company, visit Volition.
